Yan Z, Deng X, Friedman E
Department of Pathology, Upstate Medical University, State University of New York, Syracuse, New York 13210, USA.
J Biol Chem. 2001 Jan 12;276(2):1555-63. doi: 10.1074/jbc.M004553200.
Transforming growth factor-beta1 (TGF-beta1) can act as a tumor suppressor or a tumor promoter depending on the characteristics of the malignant cell. Each of three Ki-ras(G12V) transfectants of HD6-4 colon cancer cells had been shown to be more aggressive in vivo than controls in earlier studies (Yan, Z., Chen, M., Perucho, M., and Friedman, E. (1997) J. Biol. Chem. 272, 30928-30936). We now show that stable expression of oncogenic Ki-ras(G12V) converts the HD6-4 colon cancer cell line from insensitive to TGF-beta1 to growth-promoted by TGF-beta1. Each of three Ki-ras(G12V) transfectants responded to TGF-beta1 by an increase in proliferation and by decreasing the abundance of the Cdk inhibitor p21 and the tumor suppressor PTEN, whereas each of three wild-type Ki-ras transfectants remained unresponsive to TGF-beta1. The wild-type Ki-ras transfectants lack functional TGF-beta receptors, whereas all three Ki-ras(G12V) transfectants expressed functional TGF-beta receptors that bound (125)I-TGF-beta1. The previous studies showed that in cells with wild-type Ki-ras, TGF-beta receptors were not mutated, and receptor proteins were transported to the cell surface, but post-translational modification of TGF-beta receptor III (TbetaRIII) was incomplete. We now show that the betaglycan form of TbetaRIII is highly modified following translation when transiently expressed in Ki-ras(G12V) cells, whereas no such post-translational modification of TbetaRIII occurs in control cells. Antisense oligonucleotides directed to Ki-Ras decreased both TbetaRIII post-translational modification in Ki-ras(G12V) cells and TGF-beta1 down-regulation of p21, demonstrating the direct effect of mutant Ras. Therefore, one mechanism by which mutant Ki-Ras confers a more aggressive tumor phenotype is by enhancing TbetaRIII post-translational modification.
转化生长因子-β1(TGF-β1)可作为肿瘤抑制因子或肿瘤促进因子,这取决于恶性细胞的特性。在早期研究中,HD6-4结肠癌细胞的三种Ki-ras(G12V)转染子在体内均比对照更具侵袭性(Yan, Z., Chen, M., Perucho, M., and Friedman, E. (1997) J. Biol. Chem. 272, 30928 - 30936)。我们现在表明,致癌性Ki-ras(G12V)的稳定表达使HD6-4结肠癌细胞系从对TGF-β1不敏感转变为受TGF-β1促进生长。三种Ki-ras(G12V)转染子中的每一种对TGF-β1的反应都是增殖增加,同时细胞周期蛋白依赖性激酶抑制剂p21和肿瘤抑制因子PTEN的丰度降低,而三种野生型Ki-ras转染子中的每一种对TGF-β1仍无反应。野生型Ki-ras转染子缺乏功能性TGF-β受体,而所有三种Ki-ras(G12V)转染子都表达能结合(125)I-TGF-β1的功能性TGF-β受体。先前的研究表明,在具有野生型Ki-ras的细胞中,TGF-β受体未发生突变,受体蛋白被转运到细胞表面,但TGF-β受体III(TβRIII)的翻译后修饰不完全。我们现在表明,当在Ki-ras(G12V)细胞中瞬时表达时,TβRIII的β聚糖形式在翻译后会发生高度修饰,而在对照细胞中不会发生这种TβRIII的翻译后修饰。针对Ki-Ras的反义寡核苷酸降低了Ki-ras(G12V)细胞中TβRIII的翻译后修饰以及TGF-β1对p21的下调作用,证明了突变型Ras的直接作用。因此,突变型Ki-Ras赋予更具侵袭性肿瘤表型的一种机制是通过增强TβRIII的翻译后修饰。